Christine M Salvatore1, Tempe K Chen2, Sima S Toussi1, Patricia DeLaMora1, Ruta Petraitiene3, Malcolm A Finkelman4, Thomas J Walsh5. 1. Division of Pediatrics Infectious Diseases, Department of Pediatrics, New York-Presbyterian Hospital, Weill Cornell Medical College, New York. 2. Department of Pediatrics, University of California Irvine School of Medicine, Miller Children's and Women's Hospital Long Beach. 3. Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical Center of Cornell University, New York. 4. Associates of Cape Cod, Inc., East Falmouth, Massachusetts. 5. Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical Center of Cornell University, New York Department of Microbiology and Immunology, Weill Cornell Medical Center of Cornell University, New York.
Abstract
BACKGROUND: Fungal infections of the central nervous system (FICNS) are important causes of morbidity and mortality among immunocompromised pediatric patients. Standard diagnostic modalities lack the sensitivity for detecting and therapeutically monitoring these life-threatening diseases. Current molecular methods remain investigational. (1→3)-β-d-glucan (BDG) is a cell wall component found in several fungal pathogens, including Candida and Aspergillus spp. Detecting BDG in cerebrospinal fluid (CSF) may be an important approach for detecting and therapeutically monitoring FICNS. To date, there has been no study that has investigated the effectiveness of CSF BDG as a diagnostic and therapeutic marker of FICNS in children. METHODS: Serial BDG levels were measured in serum and CSF samples obtained from pediatric patients (aged 0-18 years) with a diagnosis of probable or proven Candida or Aspergillus CNS infection. RESULTS: Nine cases of FICNS were identified in patients aged 1 month to 18 years. Two patients were infected with an Aspergillus species, and 7 patients were infected with a Candida species. All the patients at baseline had detectable BDG in their CSF. Among 7 patients who completed therapy for an FICNS, all elevated CSF BDG levels decreased to <31 pg/mL. At the time of this writing, 1 patient was still receiving therapy and continued to have elevated BDG levels. One patient died from overwhelming disseminated candidiasis. The lengths of therapy for these 9 children ranged from 2 weeks to 28 months. CONCLUSION: The BDG assay is useful in diagnosing and therapeutically monitoring Candida and Aspergillus CNS infections in pediatric patients.
BACKGROUND:Fungal infections of the central nervous system (FICNS) are important causes of morbidity and mortality among immunocompromised pediatric patients. Standard diagnostic modalities lack the sensitivity for detecting and therapeutically monitoring these life-threatening diseases. Current molecular methods remain investigational. (1→3)-β-d-glucan (BDG) is a cell wall component found in several fungal pathogens, including Candida and Aspergillus spp. Detecting BDG in cerebrospinal fluid (CSF) may be an important approach for detecting and therapeutically monitoring FICNS. To date, there has been no study that has investigated the effectiveness of CSF BDG as a diagnostic and therapeutic marker of FICNS in children. METHODS: Serial BDG levels were measured in serum and CSF samples obtained from pediatric patients (aged 0-18 years) with a diagnosis of probable or proven Candida or Aspergillus CNS infection. RESULTS: Nine cases of FICNS were identified in patients aged 1 month to 18 years. Two patients were infected with an Aspergillus species, and 7 patients were infected with a Candida species. All the patients at baseline had detectable BDG in their CSF. Among 7 patients who completed therapy for an FICNS, all elevated CSF BDG levels decreased to <31 pg/mL. At the time of this writing, 1 patient was still receiving therapy and continued to have elevated BDG levels. One patient died from overwhelming disseminated candidiasis. The lengths of therapy for these 9 children ranged from 2 weeks to 28 months. CONCLUSION: The BDG assay is useful in diagnosing and therapeutically monitoring Candida and Aspergillus CNS infections in pediatric patients.
Authors: Daniel K Benjamin; Barbara J Stoll; Marie G Gantz; Michele C Walsh; Pablo J Sánchez; Abhik Das; Seetha Shankaran; Rosemary D Higgins; Kathy J Auten; Nancy A Miller; Thomas J Walsh; Abbot R Laptook; Waldemar A Carlo; Kathleen A Kennedy; Neil N Finer; Shahnaz Duara; Kurt Schibler; Rachel L Chapman; Krisa P Van Meurs; Ivan D Frantz; Dale L Phelps; Brenda B Poindexter; Edward F Bell; T Michael O'Shea; Kristi L Watterberg; Ronald N Goldberg Journal: Pediatrics Date: 2010-09-27 Impact factor: 7.124
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Anastasia P Litvintseva; Mark D Lindsley; Lalitha Gade; Rachel Smith; Tom Chiller; Jennifer L Lyons; Kiran T Thakur; Sean X Zhang; Dale E Grgurich; Thomas M Kerkering; Mary E Brandt; Benjamin J Park Journal: Clin Infect Dis Date: 2013-12-12 Impact factor: 9.079
Authors: M Cohen-Wolkowiez; P B Smith; B Mangum; W J Steinbach; B D Alexander; C M Cotten; R H Clark; T J Walsh; D K Benjamin Journal: J Perinatol Date: 2006-11-02 Impact factor: 2.521
Authors: Ruta Petraitiene; Vidmantas Petraitis; Bo Bo Win Maung; Robert S Mansbach; Michael R Hodges; Malcolm A Finkelman; Karen Joy Shaw; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2021-02-17 Impact factor: 5.191
Authors: Percy Pacora; Roberto Romero; Offer Erez; Eli Maymon; Bogdan Panaitescu; Juan Pedro Kusanovic; Adi L Tarca; Chaur-Dong Hsu; Sonia S Hassan Journal: J Matern Fetal Neonatal Med Date: 2017-12-27
Authors: Thein Myint; Felicia C Chow; Karen C Bloch; Luke Raymond-Guillen; Thomas E Davis; Patty W Wright; Laila Woc-Colburn; Raed N Khairy; Alan C Street; Tomotaka Yamamoto; Amanda Albers; L Joseph Wheat; Chadi A Hage Journal: J Clin Microbiol Date: 2018-09-25 Impact factor: 5.948
Authors: Anna R Huppler; Brian T Fisher; Thomas Lehrnbecher; Thomas J Walsh; William J Steinbach Journal: J Pediatric Infect Dis Soc Date: 2017-09-01 Impact factor: 3.164
Authors: David A Stevens; Yonglong Zhang; Malcolm A Finkelman; Demosthenes Pappagianis; Karl V Clemons; Marife Martinez Journal: J Clin Microbiol Date: 2016-08-24 Impact factor: 5.948
Authors: Vidmantas Petraitis; Ruta Petraitiene; Jessica M Valdez; Vasilios Pyrgos; Martin J Lizak; Brenda A Klaunberg; Darius Kalasauskas; Algidas Basevicius; John D Bacher; Daniel K Benjamin; William W Hope; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2019-10-07 Impact factor: 5.191